Michael Schmidt
Stock Analyst at Guggenheim
(4.91)
# 25
Out of 5,170 analysts
124
Total ratings
70.41%
Success rate
50.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Buy | $10 → $15 | $4.78 | +213.81% | 3 | Mar 18, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Buy | $34 → $30 | $16.06 | +86.80% | 3 | Mar 18, 2026 | |
| ERAS Erasca | Maintains: Buy | $12 → $20 | $15.26 | +31.06% | 2 | Mar 16, 2026 | |
| XFOR X4 Pharmaceuticals | Initiates: Buy | $12 | $4.17 | +187.77% | 1 | Mar 9, 2026 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $20 | $19.32 | +3.52% | 3 | Mar 6, 2026 | |
| ONC BeOne Medicines AG | Maintains: Buy | $400 → $410 | $282.72 | +45.02% | 5 | Feb 27, 2026 | |
| GMAB Genmab | Maintains: Buy | $45 → $40 | $25.73 | +55.46% | 4 | Feb 23, 2026 | |
| NBTX Nanobiotix | Maintains: Buy | $8 → $26 | $31.61 | -17.73% | 3 | Feb 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Buy | $92 → $160 | $99.29 | +61.14% | 5 | Jan 20, 2026 | |
| IMNM Immunome | Maintains: Buy | $25 → $35 | $20.83 | +68.03% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.89 | +145.40% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $125 | $92.95 | +34.48% | 7 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.04 | +147.52% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $11.10 | +62.16% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $5.39 | +122.63% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $11.17 | +34.29% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $34.61 | -50.88% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $22.86 | +96.85% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $18.59 | -19.31% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $79.57 | -34.65% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $10.00 | - | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $24.00 | +33.33% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $5.82 | +140.55% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $17.87 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $41.26 | +1.79% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.49 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.30 | +277.36% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $2.56 | +212.50% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $30.04 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $112 | $7.07 | +1,484.16% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.54 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.86 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.22 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $12.12 | +180.53% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $3.06 | +749.67% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.48 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $27.92 | +186.53% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.97 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $4.37 | +25.86% | 2 | Nov 7, 2017 |
CytomX Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $4.78
Upside: +213.81%
Monte Rosa Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $16.06
Upside: +86.80%
Erasca
Mar 16, 2026
Maintains: Buy
Price Target: $12 → $20
Current: $15.26
Upside: +31.06%
X4 Pharmaceuticals
Mar 9, 2026
Initiates: Buy
Price Target: $12
Current: $4.17
Upside: +187.77%
Tango Therapeutics
Mar 6, 2026
Maintains: Buy
Price Target: $18 → $20
Current: $19.32
Upside: +3.52%
BeOne Medicines AG
Feb 27, 2026
Maintains: Buy
Price Target: $400 → $410
Current: $282.72
Upside: +45.02%
Genmab
Feb 23, 2026
Maintains: Buy
Price Target: $45 → $40
Current: $25.73
Upside: +55.46%
Nanobiotix
Feb 6, 2026
Maintains: Buy
Price Target: $8 → $26
Current: $31.61
Upside: -17.73%
Revolution Medicines
Jan 20, 2026
Maintains: Buy
Price Target: $92 → $160
Current: $99.29
Upside: +61.14%
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $25 → $35
Current: $20.83
Upside: +68.03%
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $4.89
Upside: +145.40%
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $92.95
Upside: +34.48%
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $4.04
Upside: +147.52%
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $11.10
Upside: +62.16%
Aug 12, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $5.39
Upside: +122.63%
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $11.17
Upside: +34.29%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $34.61
Upside: -50.88%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $22.86
Upside: +96.85%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $18.59
Upside: -19.31%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $79.57
Upside: -34.65%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $10.00
Upside: -
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $24.00
Upside: +33.33%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $5.82
Upside: +140.55%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $17.87
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $41.26
Upside: +1.79%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.49
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $5.30
Upside: +277.36%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.56
Upside: +212.50%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $30.04
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $112
Current: $7.07
Upside: +1,484.16%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.54
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.86
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.22
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $12.12
Upside: +180.53%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $3.06
Upside: +749.67%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.48
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $27.92
Upside: +186.53%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $6.97
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $4.37
Upside: +25.86%